General Sense

Cover Block

PUBLIC

Name	General Sense
Tagline	Decoding biological olfaction from animals into digital data to build the chemical sensing layer for AI. [SOSV]
Headquarters	Alachua, Florida [LinkedIn]
Founded	2020 [LinkedIn]
Stage	Seed [Wellfound, July 2024]
Business Model	Hardware + Software
Industry	Deeptech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$5,000,000)

Links

PUBLIC

• Website: https://www.generalsense.com
• LinkedIn: https://www.linkedin.com/company/generalsense

Executive Summary

PUBLIC

General Sense is building a chemical sensing layer for artificial intelligence by decoding biological olfaction from animals into digital data in real time [SOSV]. The company's ambition is to own a frontier data modality, positioning its technology as foundational infrastructure for AI's understanding of the physical world [SOSV]. Founded in 2020, the company emerged from DARPA-backed neuroscience research and operates under the former name Canaery [LinkedIn].

Its core product is a Nose-Computer Interface (NCI) that reads neural signals directly from a dog's olfactory bulb, translating them into a digital stream [SOSV]. This approach aims to scale the capabilities of detection dogs, starting with security and defense applications where animals are already deployed but whose data is not captured [LinkedIn]. The founding team is led by CEO Westley Dang, a PhD neuroscientist, and COO Gabriel Lavella, a former DARPA engineering advisor [SOSV, My TechDecisions].

Capitalization is not publicly disclosed in detail; a $4 million seed round led by Breakout Ventures in mid-2022 is the only round with a named lead investor [SOSV, 2022]. Over the next 12 to 18 months, the primary signal for progress will be the announcement of a first named commercial or government deployment, moving beyond the research collaboration with Lawrence Livermore National Laboratory [eenewseurope.com].

Data Accuracy: YELLOW -- Core product claims are sourced from the company's investor (SOSV) and a technical publication, but funding details lack independent corroboration and market traction is unverified.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed (total disclosed ~$5,000,000)

Company Overview

PUBLIC

The company operates as General Sense, a name adopted after an earlier period as Canaery [IndieBio, 2026]. Founded in 2020 and based in Alachua, Florida, the company's origin is rooted in DARPA-backed neuroscience research, a point it emphasizes in its positioning [SOSV]. The founding team includes Westley Dang, who serves as CEO, and Gabriel Lavella, the Founder and COO [SOSV]. Dang holds a PhD in Neuroscience from The Scripps Research Institute, while Lavella is a former DARPA engineering advisor [RocketReach, 2026], [My TechDecisions, 2022].

Key milestones follow a development-focused timeline. The company secured an undisclosed seed round in February 2021 [Crunchbase, 2021]. A more substantial $4 million seed round led by Breakout Ventures closed in June 2022, which SOSV's IndieBio program announced [SOSV, 2022]. Public records indicate a subsequent seed round of $5 million in July 2024, though investor details for this round are not confirmed [Wellfound, July 2024]. Technologically, the company developed its Nose-Computer Interface (NCI) in collaboration with Lawrence Livermore National Laboratory [eenewseurope.com]. By 2025, it reported achieving the first real-time detection of chemical world data from neural activity [Internexxus, 2026].

Data Accuracy: YELLOW -- Founding details and the 2022 round are corroborated by multiple sources; the 2024 round and technological claims rely on single-source reports.

Product and Technology

MIXED

The company’s product is a direct translation of its founding premise: a hardware-software system that intercepts and digitizes the chemical intelligence of a living animal. General Sense’s core offering is a Nose-Computer Interface (NCI), a piece of hardware that reads neural signals directly from a dog’s olfactory bulb and translates them into digital data in real time [SOSV]. This positions the system not as a tool to train a better dog, but as infrastructure for capturing a new data modality. The company describes this as building the chemical sensing layer for artificial intelligence, where every deployed animal feeds a shared model that grows smarter with each sniff [SOSV].

Technically, the system rests on DARPA-backed neuroscience research [SOSV] and has been developed in collaboration with Lawrence Livermore National Laboratory [eenewseurope.com]. The public claim is that the NCI can help scent-detection animals simultaneously identify contraband like explosives and narcotics, as well as biomarkers for neurological and infectious diseases [eenewseurope.com]. A more recent, specific technical claim surfaced in 2026, stating the company had quietly built the world’s first real-time detection of the chemical world from neural activity using a very specific brain signal [Internexxus, 2026]. The product’s immediate applications are framed around security and defense, where detection dogs are already deployed but unable to scale [LinkedIn].

• Hardware-centric stack. The reliance on a physical interface implanted on or near the olfactory bulb suggests a specialized hardware engineering effort, likely involving microfabrication, signal acquisition, and wireless telemetry.
• Proprietary data pipeline. The value proposition hinges on the software that processes raw neural signals into structured, actionable chemical data, implying a machine learning stack trained on a unique, closed dataset.
• No public roadmap. The company’s website and public materials do not describe a product roadmap, feature timeline, or specific technical specifications beyond the high-level concept.

Data Accuracy: YELLOW -- Core product claims are consistent across the company's own materials and a partner lab publication, but third-party technical validation is absent.

Market Research

PUBLIC The ambition to digitize a fundamental biological sense for artificial intelligence places General Sense at the intersection of several large, established markets, but its immediate commercial path is defined by a narrow, high-stakes wedge.

Quantifying the total addressable market for a chemical sensing layer is speculative, as the company is creating a new data modality. A more concrete starting point is the existing market for biological detection, where the company aims to insert its technology. The global market for explosive, narcotic, and contraband detection systems was valued at approximately $6.8 billion in 2022 and is projected to grow to $10.5 billion by 2030 [MarketsandMarkets, 2022]. Within this, the segment for biological detection, which includes trained dogs and their handlers, represents a multi-billion dollar annual expenditure for governments and private security firms globally. The medical diagnostics market, another cited long-term application, is orders of magnitude larger, with the point-of-care diagnostics segment alone exceeding $40 billion [Grand View Research, 2023]. General Sense's infrastructure bet is that its networked platform could eventually capture value across these expansive, adjacent verticals.

Demand is driven by persistent security threats and inefficiencies in current methods. Manual canine teams, while highly effective, are constrained by scalability, handler interpretation, and the inability to log or share detection data in real time. There is a documented push within defense and homeland security agencies for technologies that enhance situational awareness and create persistent, networked surveillance [SOSV]. Concurrently, advancements in neuroscience and brain-computer interfaces, supported by agencies like DARPA, have lowered the technical barriers to reading complex neural signals in real-world settings, creating a tailwind for the underlying research [SOSV].

The most significant adjacent market is the broader field of chemical sensors and electronic noses. This is a crowded, multi-billion dollar space populated by companies developing hardware to detect specific volatile organic compounds. General Sense's differentiation is not in competing with these point sensors, but in proposing a biological system as a superior, general-purpose sensor that can be continuously trained. A key substitute market is simply the status quo: continued investment in training more dogs and handlers rather than augmenting existing ones with technology. The regulatory environment is a double-edged force. While defense procurement cycles are long and stringent, a successful demonstration with a national lab partner like Lawrence Livermore could serve as a powerful validation catalyst for adoption within government channels [eenewseurope.com].

Explosive/Narcotic Detection (2022) | 6.8 | $B
Point-of-Care Diagnostics (2023) | 40 | $B

The chart illustrates the vast scale of the terminal markets General Sense ultimately points toward, though its initial serviceable market is the fraction spent on biological detection within the security segment. The company's commercial thesis hinges on proving its technology can capture and digitize olfactory intelligence more effectively than incremental improvements in electronic sensors or canine training.

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors, not specific to the company's product. The company's own market claims are qualitative and not quantified in public sources.

Competitive Landscape

MIXED

General Sense operates in a competitive vacuum by design, defining a category where no direct commercial equivalent exists. The company’s stated ambition is not to compete with existing detection technology vendors but to create a new data modality, positioning its Nose-Computer Interface (NCI) as foundational infrastructure for chemical intelligence [SOSV]. This framing means the competitive analysis must examine adjacent substitutes and potential future entrants rather than current head-to-head rivals.

A competitive map for chemical sensing and threat detection reveals several distinct layers. The incumbent layer consists of established technologies deployed in security and diagnostics: electronic noses (e-noses) from companies like Aryballe and Alpha MOS, which use sensor arrays to detect volatile compounds; mass spectrometry and gas chromatography equipment from vendors like Thermo Fisher and Agilent; and trained animal handlers who deploy dogs without neural interfacing. The challenger layer includes startups applying machine learning to sensor data, such as Koniku, which engineers biological neurons on silicon chips for odor detection. The most adjacent substitutes are other brain-computer interface (BCI) companies operating in medical or consumer realms, like Synchron or Paradromics, whose core signal-decoding expertise could theoretically be redirected toward olfaction, though none have publicly announced such a pivot.

General Sense’s defensible edge today rests on three specific, interlocking assets. First is its proprietary access to a frontier data type: real-time neural signals from the olfactory bulb of a living, working animal. This is not merely sensor data but the brain’s encoded representation of a scent, a dataset no other entity is confirmed to be collecting at scale [SOSV]. Second is its foundational neuroscience IP, reportedly built on DARPA-backed research, which provides a technical moat around decoding these specific neural patterns [SOSV]. Third is its strategic collaboration with a national laboratory; work with Lawrence Livermore National Laboratory (LLNL) on the NCI provides credibility, access to specialized fabrication capabilities, and a pathway to early government adoption [eenewseurope.com]. This edge is durable only if the company can maintain its lead in data collection volume and model sophistication before alternatives emerge.

The company’s most significant exposure lies in the capital intensity and regulatory pathway of its chosen wedge. Security and defense procurement cycles are long, and certification for a novel neural interface on animals will require extensive validation. A well-funded incumbent like a defense prime (e.g., Leidos, Northrop Grumman) or a large diagnostics firm could decide to build or acquire similar capability, leveraging existing government contracts and regulatory affairs teams that General Sense lacks. Furthermore, the company is exposed to technological substitution from less invasive methods. If e-nose sensitivity approaches biological fidelity through advancements in nanomaterials or synthetic biology, the value proposition of a surgically implanted neural interface diminishes.

The most plausible 18-month competitive scenario hinges on proof-of-concept deployments. If General Sense successfully places its NCI systems with a named agency for a pilot program (e.g., TSA or CBP), it would validate the infrastructure thesis and likely attract follow-on capital to scale data collection. In this scenario, Koniku could emerge as a primary loser if its bioreactor-based scent detection is perceived as less direct or less scalable than reading from a biological nose already in the field. Conversely, if the company fails to secure a flagship deployment and remains in the lab, the winner would be the incumbent e-nose vendors, who would continue to incrementally improve their systems without facing disruptive competition for the chemical intelligence layer.

Data Accuracy: YELLOW -- Competitive positioning is inferred from company statements and adjacent industry mapping; no direct competitive intelligence from third-party analysts is available.

Opportunity

PUBLIC If General Sense successfully decodes biological olfaction into a scalable data stream, it could create the foundational chemical sensing layer for a new generation of AI, a market that does not currently exist.

The headline opportunity is the creation of a new category of infrastructure: the chemical intelligence platform for embodied AI. The company's core thesis, as articulated in its own materials, is that it is building "the only infrastructure that collects this data" and owns "a frontier data modality, the chemical lobe for embodied intelligence" [SOSV]. This moves beyond simply improving detection dogs to establishing a networked sensing platform where each deployed animal feeds a shared, continuously learning model [SOSV]. The plausibility of this outcome rests on the company's claimed technical milestone: the development of the world’s first real-time detection of the chemical world from neural activity using a specific brain signal [Internexxus, 2026]. This initial proof-of-concept, built on DARPA-backed neuroscience research, provides a technical wedge into the broader ambition of providing AI with a generalizable understanding of the chemical world.

Multiple, concrete paths exist for the company to scale from its initial security wedge to a category-defining platform. The scenarios below outline distinct vectors for growth, each with a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Defense & Security Standard	The Nose-Computer Interface (NCI) becomes a mandated upgrade for all scent-detection animals in U.S. and allied military, border, and law enforcement units.	A formal contract or technology transition agreement with a major defense agency like the Department of Homeland Security or a prime contractor.	The company has already collaborated with Lawrence Livermore National Laboratory (LLNL) to enhance the NCI for detecting contraband and disease biomarkers [eenewseurope.com], establishing a beachhead in the national lab ecosystem that often precedes larger defense adoption.
Biomedical Screening Network	The platform pivots to become a non-invasive, real-time diagnostic tool for early detection of neurological diseases (e.g., Parkinson's, Alzheimer's) and infectious outbreaks.	A peer-reviewed publication or clinical trial demonstrating high accuracy in detecting specific volatile organic compounds linked to disease.	The underlying technology is cited as capable of identifying biomarkers for neurological and infectious diseases [eenewseurope.com], and the long-term mission explicitly includes protecting public health [LinkedIn].
AI Foundry Partnership	General Sense becomes the exclusive provider of real-world chemical sensing data to a major AI lab (e.g., OpenAI, Anthropic) training next-generation world models.	A strategic R&D partnership announced with a leading AI research organization seeking to integrate chemical perception into multimodal models.	The company frames its data as "unlocking the sensory data needed for complete world models" [General Sense], positioning its output as a critical, missing input for advanced AI systems, a narrative that aligns with current AI research priorities.

The compounding advantage for General Sense is a data network effect that strengthens with each deployment. Every animal equipped with an NCI contributes real-time, labeled chemical data to a central model. As the model improves, its accuracy and speed increase, which in turn makes the platform more valuable to each new customer, creating a classic data moat. The company's own description suggests this flywheel is part of the design: "every deployed animal feeds a shared model that grows smarter with each sniff" [SOSV]. Early deployments in controlled environments, such as the LLNL collaboration, would provide the initial data corpus to begin this cycle.

Quantifying the size of the win requires looking at adjacent infrastructure and data platform valuations. While no direct comparable exists for a chemical intelligence layer, the company's ambition to be "infrastructure" suggests parallels to foundational AI data providers. For instance, Scale AI, which provides data annotation and evaluation infrastructure for AI development, reached a reported valuation of over $7 billion in 2021 [Bloomberg, 2021]. If the "Defense & Security Standard" scenario plays out, General Sense could command a valuation anchored to the total addressable spend on canine detection programs and their technological modernization within the defense and security sector,a multi-billion dollar annual budget. A more speculative but potentially larger outcome, per the "AI Foundry Partnership" scenario, would see the company valued as a unique data asset critical to the race for artificial general intelligence, a premise that has supported valuations in the tens of billions for companies with similarly scarce, high-fidelity data generation capabilities. This is a scenario-based illustration of potential scale, not a forecast.

Data Accuracy: YELLOW -- The framing of the opportunity and technical milestones are drawn from company and partner sources (SOSV, Internexxus, eenewseurope.com). The growth scenarios are logical extrapolations from these stated capabilities and partnerships, but lack third-party validation of commercial progress. Valuation comparables are from public market reports.

Sources

PUBLIC

1. [SOSV] General Sense - SOSV | https://sosv.com/company/general-sense/

2. [LinkedIn] General Sense | https://www.linkedin.com/company/generalsense

3. [Wellfound, July 2024] Wellfound funding page | https://wellfound.com/company/general-sense/funding

4. [My TechDecisions, 2022] New nose computer interface aims to upgrade rover's nose | https://www.rdworldonline.com/new-nose-computer-interface-aims-to-upgrade-rovers-nose-for-better-drug-detection-methods/

5. [SOSV, 2022] IndieBio’s Canaery locks in $4M for neurotech that knows what a dogs nose knows - SOSV | https://sosv.com/indiebios-canaery-locks-in-4m-for-neurotech-that-knows-what-a-dogs-nose-knows/

6. [Crunchbase, 2021] General Sense - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/canaery

7. [RocketReach, 2026] Westley Dang Email & Phone Number | General Sense CEO Contact Information | https://rocketreach.co/westley-dang-email_113339726

8. [eenewseurope.com] Nose-computer interface (NCI) for scent-detection animals ... | https://www.eenewseurope.com/en/nose-computer-interface-nci-for-scent-detection-animals/

9. [Internexxus, 2026] Summer Intern (Multiple Disciplines) - Internexxus | https://internexxus.com/internship/summer-intern-multiple-disciplines-3/

10. [IndieBio, 2026] IndieBio is Now SOSV NY & SOSV SF, Underscoring SOSV’s Leadership in Deep Tech - SOSV | https://sosv.com/indiebio-is-now-sosv-ny-sosv-sf-underscoring-sosvs-leadership-in-deep-tech/

11. [General Sense] General Sense - Home | https://www.generalsense.com/

12. [MarketsandMarkets, 2022] Explosive Detection Market Size, Share, Growth | MarketsandMarkets | https://www.marketsandmarkets.com/Market-Reports/explosive-detection-market-1002.html

13. [Grand View Research, 2023] Point Of Care Diagnostics Market Size, Share & Trends Analysis Report | Grand View Research | https://www.grandviewresearch.com/industry-analysis/point-of-care-diagnostics-market

14. [Bloomberg, 2021] Scale AI Is Now Worth $7.3 Billion in New Funding Round | https://www.bloomberg.com/news/articles/2021-04-13/scale-ai-is-said-to-be-worth-7-3-billion-in-new-funding-round